CITIGROUP GLOBAL MARKETS FUNDING LUXEMBOURG S.C.A. | Market Closed - Deutsche Boerse AG 16:21:37 07/06/2024 BST | ||
| 105.8 EUR | +0.06% |
|
| Current month | +0.54% | ||
| 1 month | +1.24% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 07/06/24 | 105.8 | +0.06% |
| 06/06/24 | 105.8 | +0.35% |
| 05/06/24 | 105.4 | -0.05% |
| 04/06/24 | 105.5 | +0.16% |
| 03/06/24 | 105.3 | +0.02% |
Delayed Quote Deutsche Boerse AG
Last update June 07, 2024 at 04:21 pm
More quotesStatic data
| Product type | Other Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Citi
|
| WKN | A3PME2 |
| ISIN | XS2650758431 |
| Date issued | 03/10/2023 |
| Strike | 651.5 kr |
| Maturity | 28/09/2028 (1573 Days) |
| Parity | 0.65 : 1 |
| Emission price | 100 € |
| Emission volume | N/A |
| Settlement | both |
| Currency | EUR |
Technical Indicators
| Highest since issue | 105.9 € |
|---|---|
| Lowest since issue | 94.74 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
984
DKK
Average target price
920.8
DKK
Spread / Average Target
-6.43%
- Stock Market
- Certificates
- Certificat
